Form 4: Alignment Healthcare CEO Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Alignment Healthcare's CEO, John E. Kao, sold a total of 90,000 shares of common stock on January 13, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- John E. Kao, the CEO of Alignment Healthcare, sold 52,386 shares of common stock at a weighted average price of $12.8092 per share on January 13, 2025.
- He also sold 37,614 shares of common stock at a weighted average price of $13.4118 per share on the same day.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2024.
- The shares were sold in multiple transactions at varying prices within the ranges of $12.23 to $13.22 and $13.24 to $13.58 respectively.
- Following these sales, Mr. Kao directly owns 2,745,253 shares and indirectly owns 2,273,100 shares through the JEK Trust.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for insider stock sales under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.
Risks
- Sales by a company's CEO could be perceived negatively by the market, potentially impacting the stock price.
Industry Context
This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans. It does not indicate any specific change in the company's performance or outlook.
Comparison to Industry Standards
- Executive stock sales are a common occurrence in publicly traded companies, especially when executed under pre-arranged 10b5-1 plans.
- Companies like UnitedHealth Group (UNH) and Humana (HUM) also see similar filings from their executives.
- The volume of shares sold by Mr. Kao is not unusual for a CEO of a company of Alignment Healthcare's size.
Stakeholder Impact
- The stock sales could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sales should mitigate any significant negative reaction.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| 01/13/2025 | Date of the stock sales by John E. Kao. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Sale, Rule 10b5-1, Alignment Healthcare, John E. Kao, ALHC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.